. 2023 Feb 20;24(4):4173. doi: 10.3390/ijms24044173

Table 2.

Potential targets for vaccine development. Selected peptides that are IgG4 unique or elicited increased IgG4:IgE ratios after one year of treatment.

Unique IgG4 Epitopes
Allergen		Consent Epitope				Corresponding Aminoacid Position
Der p 5		ELALFYLQEQINHFEEKPTKEMKDKIVAEMDTI				62–94
Der p 5		QRKDLDIFEQYNLEM				110–124
Der p 7		EEINKAVDEAVAAIEKSETFD				27–47
Blo t 5		DELNENKSKELQEKIIRELDV				58–78
Blo t 5		LKDLKETEQKVKDIQ				118–132
Blo t 6		VQHEQYDPNTIENDI				124–138
Blo t 12		KTTTEETHHSDDLIV				70–84
Blo t 13		IEGKYKLEKSDNFDKFLDELGVGF				3–26
		KNTEIKFKLGEEFEEDRADGK				57–77
		QTQYGDKEVKIVRDFQGD				93–110
Epitopes with increased igg4:ige ratios after treatment
Allergen	Corresponding aminoacid position	Peptide	Ratio IgG4:IgE		Consent Epitope		Corresponding aminoacid position
Allergen	Corresponding aminoacid position	Peptide	pre-SLIT	post-1 year	Consent Epitope		Corresponding aminoacid position
Der p 1	149–163	RNQSLDLAEQELVDC	0.21	83.5	RNQSLDLAEQELVDC		149–163
	296–310	DNGYGYFAANIDLMM	0.39	3.98	DNGYGYFAANIDLMMIEE		296–313
	299–313	YGYFAANIDLMMIEE	0.01	46.5	DNGYGYFAANIDLMMIEE		296–313
Der p 2	24–38	DCANHEIKKVLVPGC	0.23	80	DCANHEIKKVLVPGC		24–38
Der p 5	38–53	KKHDYQNEFDFLLME	0.05	26.5	KKHDYQNEFDFLLME		38–53
Der p 7	27–41	EEINKAVDEAVAAIE	3.09	102	EEINKAVDEAVAAIE		27–41
Der p 7	103–117	LLVGVHDDVVSMEYD	0.01	339.5	LLVGVHDDVVSMEYD		103–117
Der p 10	110–124	TAKLEEASQSADESE	0.12	221.5	TAKLEEASQSADESE		110–124
	146–160	NQLKEARMMAEDADR	0.01	76	NQLKEARMMAEDADRKYDEVARKLAMVEADLERAEERAETGESKIVELEEELRVVGNNLKSL		146–208
	149–163	KEARMMAEDADRKYD	0.17	161.5
	170–184	AMVEADLERAEERAE	0.22	1.8
	182–196	RAETGESKIVELEEE	13	34.88
	194–208	EEELRVVGNNLKSLE	0.27	2.37
	212–226	EKAQQREEAHEQQIR	1.55	86.5	EKAQQREEAHEQQIR		212–226
	257–271	EDELVHEKEKYKSIS	0.16	134	EDELVHEKEKYKSIS		257–271
Der p 23	74–88	KDCPGNTRWNEDEET	1.76	119	KDCPGNTRWNEDEET		74–88
Blo t 5	19–33	EHKPKKDDFRNEFDH	0.29	1.32	EHKPKKDDFRNEFDHLLIEQA		19–39
	25–39	DDFRNEFDHLLIEQA	0.93	3.96	EHKPKKDDFRNEFDHLLIEQA		19–39
	70–84	EKIIRELDVVCAMIE	3.15	127	EKIIRELDVVCAMIE		70–84
Blo t 6	127–141	EQYDPNTIENDISLL	5.39	31	VQHEQYDPNTIENDISLL		124–141
Blo t 6	187–201	NLQVGELKIVSQEEC	0.11	2.02	NLQVGELKIVSQEEC		187–201
Blo t 12	22–36	DEQTTRGRHTEPDDH	0.48	92.5	DEQTTRGRHTEPDDH		22–36
Blo t 12	97–111	EEGPIHIQEMCNKYI	0.15	26.5	EEGPIHIQEMCNKYI		97–111
Blo t 13	12–26	SDNFDKFLDELGVGF	11.17	342.25	SDNFDKFLDELGVGF		12–26
Blo t 13	96–110	YGDKEVKIVRDFQGD	0.01	3.19	YGDKEVKIVRDFQGD		96–110